Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 09 2023
18 09 2023
Historique:
received:
20
12
2022
accepted:
05
09
2023
medline:
20
9
2023
pubmed:
19
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
To determine whether Xpert bladder cancer monitor, a noninvasive PCR-based biomarker test, can predict the need for 2nd transurethral resection of the bladder (TURB) better than clinical assessment. Patients scheduled for TURB were prospectively screened. After initial TURB, patients were assigned to 2nd TURB or follow-up cystoscopy at 3 months (FU) by clinicians' discretion. Central urine cytology and Xpert monitor tests were performed prior to the 1st TURB and 2nd TURB or FU, respectively. Statistical analysis to compare clinical assessment and Xpert monitor comprised sensitivity (SENS), specificity (SPEC), NPV and PPV. Of 756 screened patients, 171 were included (114 with 2nd TURB, 57 with FU). Residual tumors were detected in 34 patients who underwent 2nd TURB, and recurrent tumors were detected in 2 patients with FU. SENS and SPEC of Xpert monitor were 83.3% and 53.0%, respectively, PPV was 32.6% and NPV was 92.1%. Clinical risk assessment outperformed Xpert monitor. In patients with pTa disease at initial TURB, Xpert monitor revealed a NPV of 96%. Xpert monitor was not superior than clinical assessment in predicting the need for 2nd TURB. It might be an option to omit 2nd TURB for selected patients with pTa disease.
Identifiants
pubmed: 37723173
doi: 10.1038/s41598-023-42088-z
pii: 10.1038/s41598-023-42088-z
pmc: PMC10507065
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15437Investigateurs
Johannes Breyer
(J)
Markus Eckstein
(M)
Danijel Sikic
(D)
Felix Wezel
(F)
Florian Roghmann
(F)
Ralph M Wirtz
(RM)
Jonas Jarczyk
(J)
Philipp Erben
(P)
Veronika Bahlinger
(V)
Franziska Goldschmidt
(F)
Guido Fechner
(G)
Maximilian Haas
(M)
Friedemann Zengerling
(F)
Christian Bolenz
(C)
Maximilian Burger
(M)
Arndt Hartmann
(A)
Maximilian C Kriegmair
(MC)
Informations de copyright
© 2023. Springer Nature Limited.
Références
Adv Exp Med Biol. 2018;1116:37-50
pubmed: 30242788
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
Scand J Urol. 2016 Jun;50(3):170-4
pubmed: 26817989
Eur Urol. 2014 Aug;66(2):253-62
pubmed: 24472711
BJU Int. 2018 Jan;121(1):29-37
pubmed: 28941000
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
J Am Soc Cytopathol. 2022 Mar-Apr;11(2):62-66
pubmed: 35094954
Int J Urol. 2022 Jul;29(7):632-638
pubmed: 35293022
Urol Oncol. 2009 Sep-Oct;27(5):514-9
pubmed: 18639472
Can Urol Assoc J. 2018 Aug;12(8):267-269
pubmed: 29629867
BJU Int. 2021 Dec;128(6):713-721
pubmed: 33793062
World J Urol. 2021 Sep;39(9):3329-3335
pubmed: 33770241
World J Urol. 2012 Dec;30(6):841-6
pubmed: 23143733
Eur Urol. 2010 Aug;58(2):185-90
pubmed: 20303646
J Endourol. 2010 Dec;24(12):2047-50
pubmed: 20929433
Eur Urol. 2019 May;75(5):853-860
pubmed: 30553612
Urol Oncol. 2021 Jul;39(7):437.e11-437.e19
pubmed: 33785220
World J Urol. 2009 Jun;27(3):295-300
pubmed: 19271220
J Urol. 2022 Apr;207(4):754-768
pubmed: 35060770
Eur Urol. 2013 Feb;63(2):234-41
pubmed: 22877502
Urology. 2005 Feb;65(2):290-4
pubmed: 15708040
J Urol. 2014 Feb;191(2):341-5
pubmed: 23973518
Urol Ann. 2016 Jan-Mar;8(1):10-5
pubmed: 26834394
Urol Int. 2014;92(2):131-5
pubmed: 23988813
BJU Int. 2016 Jul;118(1):44-52
pubmed: 26469362
Indian J Urol. 2016 Jul-Sep;32(3):232-7
pubmed: 27555684
J Endourol. 2021 Apr;35(4):490-496
pubmed: 33222525